What is PRF Technologies Ltd. (PRFX)?

PRF Technologies Ltd. (PRFX) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of PRFX?

The current price of PRFX is $0.75. Prices are updated in real time on Stocks360.

What is PRFX's price-to-earnings (PE) ratio?

PRFX's trailing twelve-month PE ratio is -0.07, based on current price and earnings per share data available on Stocks360.

What is PRFX's market capitalization?

PRFX's market capitalization is $60,415.00, placing it in the small-cap tier.

PRF Technologies Ltd. (PRFX)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$0.75

Market Cap

$60.41K

PE (TTM)

-0.07

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.06

Day Range

$0.75 – $0.78

52-wk Range

$0.69 – $7.95

Avg Volume

N/A

Volume

30.04K

PRF Technologies Ltd. (PRFX) is a publicly traded company in the Healthcare sector. Latest price: $0.75. Market cap $60.41K. Trailing PE -0.07. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $6.00 2026-10-29 · $0.75 (-87.50%)

Earnings

Most Recent

Jul 2, 2026

EPS $-1.12 vs est. $-612.00

Beat by $610.88

Proprietary Signals

Signal snapshot temporarily unavailable.

About PRF Technologies Ltd.

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.07×
P/S (TTM)	1.53×
P/B	0.06×
P/FCF (TTM)	-0.01×
EV / EBITDA	1.14×
EV / Sales	-213.05×
Earnings Yield	-952.86%
Free Cash Flow Yield	-12216.34%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$8.42M
Net Income (TTM)	-$575.67K
Free Cash Flow (TTM)	-$7.38M
Net Debt	-$8.48M
Working Capital	$9.54M
Gross Margin	-307.59%
Operating Margin	-22873.42%
Net Margin	-22521.52%
Return on Equity	-72.87%
Return on Invested Capital	-53.79%